I-BET151 treatment reduces NF-κB activity in many melanoma cell lines, especially SK-Mel-28 and Mel-JD, and in primary cell lines with vemurafenib resistance, which is related to NF-κB overexpression. This evidence concerns the gene NFKB1 and melanoma.